Long-Term Vitiligo Data Makes the Case for Early Treatment

"Long-Term Vitiligo Data Makes the Case for Early Treatment" presents two years of durability data and the case it makes for early treatment initiation.

Dr. Haumschild presents long-term data: roughly seventy percent of patients on ruxolitinib for two years achieved FVASI75, forty-two percent reached FVASI90, and about sixty-seven percent achieved TVASI50. Dr. Rosmarin calls this extremely encouraging, though he flags that the data are no longer vehicle-controlled and reflect an as-observed rather than imputed analysis. The central message, he says, is that repigmentation keeps improving well beyond one year, unlike psoriasis or atopic dermatitis, where patients typically plateau at maximum benefit much earlier. Sustained use, not a fixed treatment endpoint, is what continues to drive results in vitiligo.

Asked about durability's implications for early initiation, Dr. Rosmarin describes comparing patients originally randomized to vehicle against those started on ruxolitinib cream immediately. Even at the two-year mark, the delayed-start group had still not caught up to those treated from the beginning, meaning an initial six-month treatment delay cost patients repigmentation they never fully recovered. That finding, he says, is why he now favors offering ruxolitinib cream early in a patient's treatment course whenever appropriate.

Jason is candid that early initiation, especially for a branded therapy over a generic, is generally not welcomed by payers. Still, he suggests that if the clinical rationale is sound and patients have had a fair, reasonably long trial of less expensive options first, a lighter-weight attestation pathway to first-line topical JAK access could become plausible. He frames his position as balancing genuine fiduciary responsibility to manage costs against recognizing that innovation and improving durability data will keep pushing spend upward regardless of how conservatively policy is written, since the underlying disease and treatment need remain constant.

In "Rethinking Safety Perceptions Around JAK Inhibitors in Vitiligo," Dr. Desai will confront the safety perceptions that still shadow JAK inhibitor use in vitiligo.